```html

Exudative Age‑Related Macular Degeneration (Wet AMD)

Overview

Exudative age‑related macular degeneration (AMD), also called “wet” AMD, is a progressive eye disease in which abnormal blood vessels grow beneath the macula—the central portion of the retina responsible for sharp, straight‑ahead vision. These new vessels are fragile and leak fluid or blood, causing rapid loss of central vision.

AMD predominantly affects older adults. In the United States, about 12 million people aged 50 and older have some form of AMD, and roughly 10‑15 % develop the exudative (wet) form. Worldwide, the International Agency for the Prevention of Blindness estimates that AMD is the leading cause of irreversible blindness in people over 60, accounting for up to 8.7 % of global blindness cases.

While “wet” AMD is less common than the “dry” (atrophic) form, it causes the majority of severe vision loss associated with AMD because the leakage can damage photoreceptor cells quickly.

Symptoms

Symptoms often appear suddenly or progress over weeks. Not every person experiences all of them, but the following list captures the most frequently reported signs:

• Blurred or distorted central vision – lines may appear wavy or bent (metamorphopsia).
• Dark or empty spot in the centre of the visual field – a “hole” that makes reading, driving, or recognizing faces difficult.
• Reduced ability to see colors vividly – colors may look faded or washed out.
• Difficulty with fine tasks – trouble threading a needle, reading small print, or using a smartphone.
• Rapid decline in vision – unlike dry AMD, wet AMD can progress from mild to severe loss within days to weeks.
• Visual “flashes” or floaters – caused by bleeding under the retina.
• Decreased contrast sensitivity – objects may blend into the background.

If you notice any sudden change in central vision, contact an eye‑care professional promptly.

Causes and Risk Factors

Wet AMD results from a complex interplay of genetic, environmental, and systemic factors.

Primary Pathophysiology

The disease is driven by choroidal neovascularization (CNV)—the growth of new, abnormal blood vessels from the choroid (the vascular layer beneath the retina) into the sub‑retinal space. These vessels are leaky, leading to fluid accumulation (exudation), hemorrhage, and scar formation that disrupt photoreceptor function.

Key Risk Factors

• Age – Risk rises sharply after age 60; prevalence doubles every decade.
• Genetics – Variants in the CFH (complement factor H) and ARMS2 genes increase susceptibility. First‑degree relatives of someone with AMD have a 2‑3‑fold higher risk.
• Smoking – Current smokers have a 2‑3× higher risk; former smokers retain elevated risk for years after quitting.
• Race/Ethnicity – Caucasians are most affected; African‑American and Asian populations have lower prevalence but can still develop wet AMD.
• Gender – Slightly more common in women, likely due to longer life expectancy.
• Cardiovascular disease – Hypertension, atherosclerosis, and high cholesterol correlate with higher incidence.
• Obesity – Body mass index (BMI) > 30 is linked to increased AMD risk.
• Diet low in antioxidants – Insufficient lutein, zeaxanthin, omega‑3 fatty acids, and vitamins C/E may predispose to disease progression.

Diagnosis

Early detection is crucial because timely treatment can preserve vision. Diagnosis is typically made by an ophthalmologist or retina specialist using a combination of clinical examination and imaging tests.

Clinical Eye Exam

• Visual acuity test – Measures how clearly you can see at various distances.
• Amsler grid – A simple home tool; distortion or missing squares suggest macular changes.
• Dilated fundus examination – Allows the doctor to view the retina and macula directly.

Imaging Studies

• Optical Coherence Tomography (OCT) – High‑resolution cross‑sectional images that reveal fluid, thickening, or scar tissue under the retina. OCT is the gold standard for detecting CNV.
• Fluorescein Angiography (FA) – An intravenous dye highlights leaking blood vessels; useful for mapping the extent of CNV.
• Indocyanine Green Angiography (ICGA) – Better for visualizing deeper choroidal vessels, especially in polypoidal choroidal vasculopathy.
• Fundus Autofluorescence (FAF) – Shows metabolic changes in retinal pigment epithelium, aiding in disease monitoring.

Treatment Options

While there is no cure, several therapies can halt or even reverse vision loss in many patients.

Anti‑VEGF Injections

Vascular endothelial growth factor (VEGF) fuels abnormal vessel growth. Intravitreal anti‑VEGF agents block this signal.

• Ranibizumab (Lucentis) – FDA‑approved for AMD; typically 1 mg monthly or treat‑and‑extend protocol.
• Aflibercept (Eylea) – Binds VEGF‑A, VEGF‑B, and PlGF; dosing often every 8 weeks after initial loading.
• Bevacizumab (Avastin) – Off‑label, less expensive; similar efficacy in many studies.
• Faricimab (Vabysmo) – Newer agent targeting VEGF‑A and Ang‑2; may extend intervals up to 16 weeks.

Most patients require a series of injections; about 70‑80 % maintain or improve visual acuity with regular treatment (Mayo Clinic, 2023).

Photodynamic Therapy (PDT)

Involves an intravenous photosensitizing drug (verteporfin) activated by a low‑energy laser, selectively closing abnormal vessels. PDT is now mostly reserved for polypoidal choroidal vasculopathy or when anti‑VEGF therapy is contraindicated.

Laser Photocoagulation

Direct thermal laser can seal leaking vessels but also damages surrounding retina, limiting its use to extrafoveal lesions.*

Emerging & Adjunctive Therapies

• Suspension of complement pathway inhibitors – Trials (e.g., pegcetacoplan) suggest slowed progression of dry AMD, potentially reducing conversion to wet AMD.
• Gene therapy – Ongoing Phase III studies aim to provide long‑lasting VEGF suppression with a single sub‑retinal injection.
• Stem‑cell based retinal pigment epithelium transplantation – Early‑phase research.

Lifestyle and Nutritional Support

While not a substitute for medical therapy, the Age‑Related Eye Disease Study (AREDS2) formulation—high‑dose vitamin C (500 mg), vitamin E (400 IU), lutein (10 mg), zeaxanthin (2 mg), zinc (80 mg as zinc oxide), and copper (2 mg)—has been shown to lower the risk of progression to advanced AMD by ~25 % in those with intermediate disease.

Living with Exudative Age‑Related Macular Degeneration

Adapting daily life can help maintain independence and quality of life.

Vision‑Enhancing Strategies

• Low‑vision aids – Magnifiers, high‑contrast reading glasses, and electronic video magnifiers.
• Custom lighting – Bright, glare‑free LED lamps positioned to reduce shadows.
• Smartphone apps – Voice‑over, screen‑reader, and large‑print apps (e.g., Seeing AI, Be My Eyes).
• Contrast‑enhancing filters – Yellow or orange tinted lenses can improve contrast for some users.

Occupational and Home Modifications

• Label medication bottles and pantry items with large print or tactile markers.
• Arrange furniture to create clear pathways, reducing fall risk.
• Use tactile or auditory kitchen appliances (e.g., talking kitchen scales).
• Consider a “buddy system” when driving; many states allow restricted‑vision drivers to obtain a conditional license.

Emotional & Social Support

Vision loss can lead to anxiety or depression. Reach out to:

• Low‑vision rehabilitation services (often covered by Medicare).
• Support groups such as the Macular Degeneration Association.
• Psychologists or counselors experienced in chronic‑illness coping.

Prevention

Because many risk factors are modifiable, preventive measures can lower the chance of developing wet AMD or slow its progression.

• Never smoke – If you smoke, seek cessation programs; nicotine replacement or prescription meds (varenicline, bupropion) are effective.
• Maintain a heart‑healthy diet – Emphasize leafy greens (spinach, kale), fatty fish (salmon, sardines), nuts, and colorful fruits.
• Exercise regularly – ≥150 minutes of moderate aerobic activity per week improves vascular health.
• Control systemic conditions – Keep blood pressure, cholesterol, and blood sugar within target ranges.
• Protect eyes from UV and blue light – Wear sunglasses with 100 % UV protection; consider lenses with blue‑light filtration for prolonged screen use.
• Regular eye exams – Annual dilated retinal examinations after age 50; earlier if you have a family history.
• Supplement wisely – Discuss AREDS2 formulations with your ophthalmologist, especially if you have intermediate or advanced dry AMD.

Complications

If untreated or inadequately managed, wet AMD can lead to serious sequelae:

• Permanent central scotoma – Irreversible blind spot that impairs reading and face recognition.
• Disciform scar formation – Fibrotic tissue replaces healthy retina, causing permanent vision loss.
• Subretinal hemorrhage – Large bleed can cause sudden severe vision loss and may require surgical evacuation.
• Geographic atrophy – Progressive loss of retinal pigment epithelium that may follow chronic anti‑VEGF therapy in a minority of patients.
• Psychosocial impact – Increased risk of depression, social isolation, and reduced functional independence.

When to Seek Emergency Care

References

• Mayo Clinic. “Wet age‑related macular degeneration.” Updated 2023. https://www.mayoclinic.org/…
• American Academy of Ophthalmology. “Age‑Related Macular Degeneration Preferred Practice Pattern.” 2022.
• National Eye Institute (NEI). “Age‑Related Macular Degeneration.” 2022. https://www.nei.nih.gov/…
• U.S. Centers for Disease Control and Prevention. “Vision Health Initiative.” 2021. https://www.cdc.gov/…
• Age‑Related Eye Disease Study 2 Research Group. “Secondary analysis of the AREDS2 formulation.” *JAMA Ophthalmology*. 2020.
• World Health Organization. “Global prevalence of vision impairment 2020.” WHO Vision Report, 2022.

```